Can a new therapy curb violence in young psychosis patients?
NCT ID NCT05756855
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This small pilot study tests a behavioral therapy called PICASSO, designed to help young adults (ages 16-30) with early psychosis who have shown violent behavior. The therapy uses cognitive behavioral techniques to address anger and violence. The study will check if the therapy is acceptable and feasible for use in clinics, but it is too small to prove it works.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- cognitive behavioral therapy (PICASSO)
- What this could lead to
- If this therapy is found to be acceptable and feasible, it could lead to a larger study testing whether it actually reduces violent behavior in young people with early psychosis.
- What could go wrong
- This is a very small pilot study with only 15 participants, no control group, and no direct measure of violence reduction. The results may not apply to broader populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
15 people
The number who actually took part.
- Started
-
Mar 2024
- Expected to finish
-
Aug 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
16 to 30 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria for EIS participants: * Ages 16 to 30 who have experienced nonaffective psychosis with a diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, other specified/unspecified schizophrenia spectrum and other psychotic disorders (International Classification of Disease Clinical Modification (ICD-10-CM) Diagnosis Code F20.x) * Receive First Episode Psychosis (FEP) treatment in one of OnTrackNY clinics/sites with an eligible EIS clinicians * Willing to participate in research interviews after each study visit during the study period Exclusion Criteria: * Unable to provide informed consent * Not fluent (speaking, reading, writing) in English
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Delusional disorder are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
New York State Psychiatric Institute
New York, New York, 10032, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Your voice may reveal if You're taking your psychiatric medication
- Scientists probe brain's reward system in mental illness
- New schizophrenia drug targets brain glutamate, not dopamine
- New drug candidate takes aim at schizophrenia symptoms
- New schizophrenia drug goes Head-to-Head with standard antipsychotics in Long-Term trial
- Five-Year safety check for experimental schizophrenia drug